The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women.
Abstract | BACKGROUND: The problems of adherence to energy restriction in humans are well known. OBJECTIVE: DESIGN: Randomized comparison of a 25% energy restriction as IER (∼ 2710 kJ/day for 2 days/week) or CER (∼ 6276 kJ/day for 7 days/week) in 107 overweight or obese (mean (± s.d.) body mass index 30.6 (± 5.1) kg m(-2)) premenopausal women observed over a period of 6 months. Weight, anthropometry, biomarkers for breast cancer, diabetes, cardiovascular disease and dementia risk; insulin resistance (HOMA), oxidative stress markers, leptin, adiponectin, insulin-like growth factor (IGF)-1 and IGF binding proteins 1 and 2, androgens, prolactin, inflammatory markers ( high sensitivity C-reactive protein and sialic acid), lipids, blood pressure and brain-derived neurotrophic factor were assessed at baseline and after 1, 3 and 6 months. RESULTS: CONCLUSION:
|
Authors | M N Harvie, M Pegington, M P Mattson, J Frystyk, B Dillon, G Evans, J Cuzick, S A Jebb, B Martin, R G Cutler, T G Son, S Maudsley, O D Carlson, J M Egan, A Flyvbjerg, A Howell |
Journal | International journal of obesity (2005)
(Int J Obes (Lond))
Vol. 35
Issue 5
Pg. 714-27
(May 2011)
ISSN: 1476-5497 [Electronic] England |
PMID | 20921964
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Adult
- Biomarkers
(metabolism)
- Breast Neoplasms
(prevention & control)
- Caloric Restriction
- Cardiovascular Diseases
(prevention & control)
- Feasibility Studies
- Female
- Humans
- Insulin Resistance
- Metabolic Syndrome
(metabolism, therapy)
- Middle Aged
- Overweight
(metabolism, therapy)
- Patient Compliance
(statistics & numerical data)
- Risk Factors
- Weight Loss
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|